WEALTHFRONT CORP Income Taxes Disclosure
| Fiscal Year Ended January 31, | |||||||||||||||||
| 2026 | 2025 | 2024 | |||||||||||||||
| United States | (101,264) | 139,229 | 78,589 | ||||||||||||||
| Foreign | 16 | — | — | ||||||||||||||
| Income (loss) before income taxes | $ | (101,248) | $ | 139,229 | $ | 78,589 | |||||||||||
| Fiscal Year Ended January 31, | |||||||||||||||||
| 2026 | 2025 | 2024 | |||||||||||||||
| Current expense (benefit): | |||||||||||||||||
| Federal | $ | — | $ | 1,200 | $ | — | |||||||||||
| State | 369 | 3,774 | 1,623 | ||||||||||||||
| Foreign | 4 | — | — | ||||||||||||||
| Deferred tax expense (benefit): | |||||||||||||||||
| Federal | (46,390) | (43,252) | — | ||||||||||||||
| State | (13,165) | (16,940) | — | ||||||||||||||
| Foreign | $ | — | $ | — | $ | — | |||||||||||
Total provision for (benefit from) income taxes | $ | (59,182) | $ | (55,218) | $ | 1,623 | |||||||||||
| Fiscal Year Ended January 31, 2026 | |||||||||||
Federal tax (benefit) at statutory rate | $ | (21,263) | 21.0 | % | |||||||
| State tax (benefit) at statutory rate, net of federal benefit* | (14,261) | 14.1 | % | ||||||||
| Foreign tax effects | 1 | — | % | ||||||||
| Effect of cross-border tax laws | 23 | — | % | ||||||||
| Tax credits: | |||||||||||
| Research and development credits | (13,845) | 13.7 | % | ||||||||
| Change in valuation allowance | — | — | % | ||||||||
| Nontaxable or nondeductible items: | |||||||||||
| Stock based compensation | (43,983) | 43.4 | % | ||||||||
| Executive compensation | 30,156 | (29.8) | % | ||||||||
| Other | (28) | 0.1 | % | ||||||||
| Changes in unrecognized tax benefits: | |||||||||||
| Reserve on research and development credits | 5,584 | (5.5) | % | ||||||||
| Other adjustments to prior year tax estimates | $ | (1,566) | 1.6 | % | |||||||
| Provision for (benefit from) income taxes | $ | (59,182) | 58.6 | % | |||||||
| Fiscal Year Ended January 31, | |||||||||||
| 2025 | 2024 | ||||||||||
Federal tax (benefit) at statutory rate | 21.0 | % | 21.0 | % | |||||||
State tax (benefit) at statutory rate, net of federal benefit | 1.9 | 4.4 | |||||||||
Change in valuation allowance | (57.6) | (17.1) | |||||||||
Stock-based compensation expense | (2.7) | (4.3) | |||||||||
Financial instrument fair value change | (2.3) | 1.2 | |||||||||
| Research and development tax credits | (1.1) | (4.8) | |||||||||
Other | 1.0 | 1.8 | |||||||||
Provision for (benefit from) income taxes | (39.8) | % | 2.2 | % | |||||||
| Fiscal Year Ended January 31, 2026 | |||||
| Federal | $ | 1,500 | |||
| State and local: | |||||
| Massachusetts | 159 | ||||
| New Jersey | 146 | ||||
| New York State | 124 | ||||
| All other state and local | 561 | ||||
| Foreign | — | ||||
| Income taxes paid, net of amounts refunded | $ | 2,490 | |||
| January 31, | |||||||||||
| 2026 | 2025 | ||||||||||
Deferred tax assets | |||||||||||
Accruals | $ | 325 | $ | 280 | |||||||
Fixed assets | 367 | 260 | |||||||||
Net operating loss carryforwards | 51,626 | 16,988 | |||||||||
| Research and development tax credits, net of reserves | 26,472 | 10,865 | |||||||||
Stock-based compensation expense | 25,363 | 15,315 | |||||||||
Lease liability | 2,724 | 3,488 | |||||||||
Research and experimental expenditures capitalization | 15,260 | 16,063 | |||||||||
| Intangible assets | 515 | — | |||||||||
Other | — | 791 | |||||||||
Gross deferred tax assets | 122,652 | 64,050 | |||||||||
Valuation allowance | — | — | |||||||||
Deferred tax assets, net of valuation allowance | 122,652 | 64,050 | |||||||||
Deferred tax liabilities | |||||||||||
Intangible assets | — | (922) | |||||||||
ROU asset | (2,280) | (2,934) | |||||||||
Other | (623) | — | |||||||||
Total deferred tax liabilities | (2,903) | (3,856) | |||||||||
Deferred tax assets, net | $ | 119,749 | $ | 60,194 | |||||||
| Fiscal Year Ended January 31, | |||||||||||||||||
| 2026 | 2025 | 2024 | |||||||||||||||
| Unrecognized tax benefits as of the beginning of the year | $ | 8,052 | $ | 6,661 | $ | 5,435 | |||||||||||
| Increase in tax positions for prior years | 415 | — | — | ||||||||||||||
| Decrease in tax positions for prior years | — | — | — | ||||||||||||||
| Increase in tax positions for current year | 5,964 | 1,391 | 1,226 | ||||||||||||||
| Decrease in tax positions for current year | — | — | — | ||||||||||||||
| Settlements | — | — | — | ||||||||||||||
| Lapse from statute of limitations | — | — | — | ||||||||||||||
| Unrecognized tax benefits as of the end of the year | 14,431 | 8,052 | 6,661 | ||||||||||||||
Want the next WEALTHFRONT CORP income taxes disclosure the moment it drops?
Set a Sentinel and we'll alert you the moment WEALTHFRONT CORP's next filing hits EDGAR. No credit card, your email never gets sold.
About Income Taxes Disclosures
The income tax disclosure reveals how much a company actually pays in taxes versus what the statutory rate would predict. Analysts focus on the effective tax rate (ETR) reconciliation, which breaks down every item driving the gap between the 21% federal rate and the company's reported ETR — including R&D credits, foreign rate differentials, and state taxes. Deferred tax assets (DTAs) and their valuation allowances signal management's confidence in future profitability: a rising allowance suggests the company doubts it can use accumulated tax benefits. Uncertain tax benefit (UTB) reserves quantify exposure to IRS challenges on aggressive positions.
Key signals to watch: sudden ETR drops without clear operational reasons, large increases in valuation allowances, growing UTB balances, and significant unremitted foreign earnings. Post-TCJA, pay attention to GILTI and BEAT provisions that affect multinational tax structures. Compare the cash taxes paid (from the cash flow statement) against the income tax provision to gauge earnings quality.